RAD001 (Everolimus) and Pasireotide (SOM230) LAR
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uveal Melanoma
Conditions
Uveal Melanoma
Trial Timeline
Nov 1, 2010 → Jun 1, 2016
NCT ID
NCT01252251About RAD001 (Everolimus) and Pasireotide (SOM230) LAR
RAD001 (Everolimus) and Pasireotide (SOM230) LAR is a phase 2 stage product being developed by Novartis for Uveal Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01252251. Target conditions include Uveal Melanoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01252251 | Phase 2 | Completed |
Competing Products
20 competing products in Uveal Melanoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pembrolizumab + Lenvatinib | Eisai | Phase 2 | 52 |
| Selumetinib, 100mg + Selumetinib, 125mg + Selumetinib, 150mg + Selumetinib, 175mg + Selumetinib, 200mg + Selumetinib, 225mg | AstraZeneca | Phase 1 | 33 |
| Pembrolizumab + Entinostat | Merck | Phase 2 | 52 |
| Pembrolizumab + Olaparib | Merck | Phase 2 | 52 |
| Pembrolizumab 25 MG/1 ML Intravenous Solution | Merck | Phase 2 | 52 |
| AEB071 | Novartis | Phase 1 | 33 |
| LXS196 + LXS196 and HDM201 | Novartis | Phase 1 | 33 |
| DYP688 | Novartis | Phase 1/2 | 41 |
| ranibizumab + triamcinolone acetonide | Novartis | Phase 2/3 | 65 |
| Crizotinib | Pfizer | Phase 2 | 51 |
| Dacarbazine + Sunitinib | Pfizer | Phase 2 | 51 |
| AEB071 + MEK162 | Pfizer | Phase 1/2 | 40 |
| Binimetinib + Belinostat | Pfizer | Phase 2 | 51 |
| Ipilimumab + Nivolumab | Bristol Myers Squibb | Phase 1 | 32 |
| Nivolumab + Relatlimab | Bristol Myers Squibb | Phase 2 | 51 |
| ipilimumab + Nivolumab | Bristol Myers Squibb | Phase 2 | 51 |
| ZIV-Aflibercept + Cemiplimab | Sanofi | Phase 2 | 51 |
| Ziv-Aflibercept | Regeneron Pharmaceuticals | Phase 2 | 51 |
| XmAb®23104 + Yervoy® (ipilimumab) | ICON plc. | Phase 1 | 30 |
| IDE196 + Binimetinib + Crizotinib | IDEAYA Biosciences | Phase 1/2 | 36 |